We currently await completion of the ongoing ALCHEMIST trial investigating this question. A number of studies in the past treated NSCLC patients with adjuvant EGFR TKI regardless of mutational status. More recently, ADJUVANT (NCT01405079) is the first randomized trial to compare the EGFR TKI ge...